USA Illumina’s newly appointed CEO, Jacob Thaysen, will take the reins of the gene sequencing giant at the end of September. Falling heir to the difficulties that have plagued the company since its botched acquisition of cancer blood test maker Grail, Thaysen will have to confront the company’s legal tangles with…
China 2019 was a landmark year for the Chinese healthcare industry.* Since the publication of the ‘Healthy China 2030’ blueprint in 2016 by the Chinese government, the entire sector has been virtually turned upside down. Against the warm backdrop of regulatory support, a series of policy changes were unveiled in the…
China Li Qing of Illumina China discusses his recent move to the company, the strategic significance of the China market to Illumina global, and the competitive landscape for next generation sequencing (NGS) in China. 2018 was a milestone year for Illumina China because we received NMPA approval of our diagnostic…
See our Cookie Privacy Policy Here